Key Drivers
- Margin Compression
- Rising Leverage
- Cash Still Positive
AIAI Summary
ALKS is no longer a pure growth story—the investment case now hinges on whether product momentum and free cash flow can outpace rising leverage and interest expense, because the latest quarter showed operating cash strength but pretax earnings turned negative and the stock will likely stay a “show me” name until debt pressure eases and margins recover.
Price Chart
Financial Metrics
Deep Analysis
Research tool. Not personalized advice.
Fundamental Analysis
Key Financial Insights:
- •Margin Compression
- •Rising Leverage
- •Cash Still Positive
ALKS remains financially strong on a full-year basis, but the latest quarter showed weaker margins, higher leverage, and far more expensive valuation metrics as earnings compressed.
Price Behavior
Key Price Behavior Insights:
- •Lower-highs trend
- •Defended support
- •Capped rallies
ALKS has weakened over the last month with lower highs and lower lows, but repeated support near $48.34–$48.37 keeps the pullback constructive until it reclaims $50.3–$50.5 and then the low-$52s.
Gradual slide from the low $50s to $49.06 over the last month shows weakening momentum
Sentiment & News
Key News Insights:
- •Revenue Growth
- •Orexin Pipeline
- •Mixed Reaction
Alkermes beat Q2 expectations with $496M revenue and break-even EPS, driven by proprietary product growth and LUMRYZ, though the stock saw a mixed reaction amid some institutional trimming.
The results and pipeline progress support ALKS's longer-term outlook, but near-term sentiment may stay mixed due to selective selling and an uneven market response
Similar Companies in Healthcare
Other companies in the same sector with AI ratings